24 results on '"Jessica Kumar"'
Search Results
2. The Transformative Possibilities of the Microbiota and Mycobiota for Health, Disease, Aging, and Technological Innovation
- Author
-
Lucas Jones, Jessica Kumar, Adil Mistry, Thriveen Sankar Chittoor Mana, George Perry, V. Prakash Reddy, and Mark Obrenovich
- Subjects
aging ,microbiota ,mycobiota ,gut-brain-axis ,CRISPR ,blood–brain barrier ,leaky gut ,leaky brain ,autism ,schizophrenia ,transsulfuration ,synbiotics ,parkinson disease ,Alzheimer’s disease ,Biology (General) ,QH301-705.5 - Abstract
The gut microbiota is extremely important for the health of the host across its lifespan. Recent studies have elucidated connections between the gut microbiota and neurological disease and disorders such as depression, anxiety, Alzheimer’s disease (AD), autism, and a host of other brain illnesses. Dysbiosis of the normal gut flora can have negative consequences for humans, especially throughout key periods during our lifespan as the gut microbes change with age in both phenotype and number of bacterial species. Neurologic diseases, mental disorders, and euthymic states are influenced by alterations in the metabolites produced by gut microbial milieu. We introduce a new concept, namely, the mycobiota and microbiota-gut-brain neuroendocrine axis and discuss co-metabolism with emphasis on means to influence or correct disruptions to normal gut flora throughout the lifespan from early development to old age. These changes involve inflammation and involve the permeability of barriers, such as the intestine blood barrier, the blood–brain barrier, and others. The mycobiota and microbiota–gut–brain axis offer new research horizons and represents a great potential target for new therapeutics, including approaches based around inflammatory disruptive process, genetically engineered drug delivery systems, diseased cell culling “kill switches„, phage-like therapies, medicinal chemistry, or microbial parabiosis to name a few.
- Published
- 2019
- Full Text
- View/download PDF
3. A Cryptic Case of an Anaerobic Hepatic Abscess Following a Cesarean Section
- Author
-
Andrew M Cyr, Marc Perlman, Cassandra L Denefrio, Jessica Kumar, and Alan Sanders
- Subjects
General Engineering - Published
- 2023
4. Effect of Prostate Artery Embolization on Erectile Function – A Single Center Experience of 167 Patients
- Author
-
Shivank Bhatia, Vedant Acharya, Hamed Jalaeian, Jessica Kumar, Evan Bryant, Andrew Richardson, Kseniia Malkova, Sardis Harward, Vishal Sinha, Issam Kably, and Bruce R. Kava
- Subjects
Psychiatry and Mental health ,Endocrinology ,Reproductive Medicine ,Urology ,Endocrinology, Diabetes and Metabolism - Abstract
Background Prostate artery embolization (PAE) is an emerging therapy for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Aim This retrospective study was conducted to assess the effect of prostate artery embolization (PAE) on erectile function in a cohort of patients with LUTS attributable to BPH at 3-months after the procedure. Methods A retrospective review was performed on 167 patients who underwent PAE. Data collected included Sexual Health Inventory in Men (SHIM) scores at 3, 6, and 12 months post-PAE, in conjunction with the International Prostate Symptom Scores (IPSS), Quality of Life (QoL) scores, and prostate volumes. Primary outcome was erectile function as assessed by SHIM scores at 3 months after PAE. An analysis was performed to identify patients with a ±5-point SHIM change to group them according to this minimum clinically significant difference in erectile function. Adverse events were recorded using the Clavien-Dindo (CD) classification. Outcomes At 3 months following PAE, median IPSS decreased by 16.0 [IQR, 9.0–22.0] points, median QOL decreased by 4.0 [IQR, 2.0–5.0] points, and median prostate volume decreased by 33 g [IQR, 14–55]. Results Median SHIM score was 17.0 [IQR, 12.0–22.0] at baseline, 18.0 [IQR, 14.0–23.0] at 3 months [P = .031], 19.0 [IQR, 14.5–21.5] at 6 months [P = .106] and 20 [IQR, 16.0–24.0] at 12 months [P = .010] following PAE. In patients with no erectile dysfunction (ED) at baseline, 21% (n = 9) reported some degree of decline in erectile function post-PAE. However, 38% (n = 40) of patients who presented with mild-to-moderate ED reported improvement in their erectile function 3 months following PAE. Overall, the changes in baseline SHIM score were relatively small; 82% (n = 137) of patients did not have more than 5 points of change in their SHIM scores at 3 months following PAE. Clinical Implications Our findings suggest PAE has no adverse impact on erectile function for most patients. Strengths & Limitations The study was performed at a single center with 1 operator’s experience, and is retrospective with no control group. Conclusion Findings suggest that prostate artery embolization has no adverse effect on erectile function in the majority of patients with LUTS attributable to BPH at 3 months after the procedure.
- Published
- 2022
5. Covid-19 Vaccine Effectiveness in New York State
- Author
-
Emily Lutterloh, Vajeera Dorabawila, Jessica Kumar, Meng Wu, Delia Easton, Rebecca Hoen, Danielle Greene, Mary Beth Conroy, Ursula E. Bauer, Eli S. Rosenberg, Dina Hoefer, and Howard A. Zucker
- Subjects
Adult ,Drug ,medicine.medical_specialty ,Adolescent ,Coronavirus disease 2019 (COVID-19) ,media_common.quotation_subject ,Population ,New York ,Vaccine Efficacy ,Cohort Studies ,Young Adult ,State (polity) ,Humans ,Medicine ,education ,BNT162 Vaccine ,Aged ,media_common ,education.field_of_study ,Ad26COVS1 ,SARS-CoV-2 ,business.industry ,Incidence ,Age Factors ,COVID-19 ,General Medicine ,Middle Aged ,Hospitalization ,Family medicine ,Original Article ,business ,2019-nCoV Vaccine mRNA-1273 - Abstract
Background Population-based data from the United States on the effectiveness of the three coronavirus disease 2019 (Covid-19) vaccines currently authorized by the Food and Drug Administration are limited. Whether declines in effectiveness are due to waning immunity, the B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or other causes is unknown. Methods We used data for 8,690,825 adults in New York State to assess the effectiveness of the BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines against laboratory-confirmed Covid-19 and hospitalization with Covid-19 (i.e., Covid-19 diagnosed at or after admission). We compared cohorts defined according to vaccine product received, age, and month of full vaccination with age-specific unvaccinated cohorts by linking statewide testing, hospital, and vaccine registry databases. We assessed vaccine effectiveness against Covid-19 from May 1 through September 3, 2021, and against hospitalization with Covid-19 from May 1 through August 31, 2021. Results There were 150,865 cases of Covid-19 and 14,477 hospitalizations with Covid-19. During the week of May 1, 2021, when the delta variant made up 1.8% of the circulating variants, the median vaccine effectiveness against Covid-19 was 91.3% (range, 84.1 to 97.0) for BNT162b2, 96.9% (range, 93.7 to 98.0) for mRNA-1273, and 86.6% (range, 77.8 to 89.7) for Ad26.COV2.S. Subsequently, effectiveness declined contemporaneously in all cohorts, from a median of 93.4% (range, 77.8 to 98.0) during the week of May 1 to a nadir of 73.5% (range, 13.8 to 90.0) around July 10, when the prevalence of the delta variant was 85.3%. By the week of August 28, when the prevalence of the delta variant was 99.6%, the effectiveness was 74.2% (range, 63.4 to 86.8). Effectiveness against hospitalization with Covid-19 among adults 18 to 64 years of age remained almost exclusively greater than 86%, with no apparent time trend. Effectiveness declined from May through August among persons 65 years of age or older who had received BNT162b2 (from 94.8 to 88.6%) or mRNA-1273 (from 97.1 to 93.7%). The effectiveness of Ad26.COV2.S was lower than that of the other vaccines, with no trend observed over time (range, 80.0 to 90.6%). Conclusions The effectiveness of the three vaccines against Covid-19 declined after the delta variant became predominant. The effectiveness against hospitalization remained high, with modest declines limited to BNT162b2 and mRNA-1273 recipients 65 years of age or older.
- Published
- 2022
6. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater-New York, June-August 2022
- Author
-
Ruth, Link-Gelles, Emily, Lutterloh, Patricia Schnabel, Ruppert, P Bryon, Backenson, Kirsten, St George, Eli S, Rosenberg, Bridget J, Anderson, Meghan, Fuschino, Michael, Popowich, Chitra, Punjabi, Maria, Souto, Kevin, McKay, Samuel, Rulli, Tabassum, Insaf, Dustin, Hill, Jessica, Kumar, Irina, Gelman, Jaume, Jorba, Terry Fei Fan, Ng, Nancy, Gerloff, Nina B, Masters, Adriana, Lopez, Kathleen, Dooling, Shannon, Stokley, Sarah, Kidd, M Steven, Oberste, Janell, Routh, and Vivian Q, Yang
- Subjects
Transplantation ,Health (social science) ,Epidemiology ,SARS-CoV-2 ,Health, Toxicology and Mutagenesis ,New York ,COVID-19 ,Infant ,General Medicine ,Wastewater ,Poliovirus ,Health Information Management ,Poliovirus Vaccine, Oral ,Immunology and Allergy ,Humans ,Pharmacology (medical) ,Public Health ,Poliomyelitis - Abstract
On July 18, 2022, the New York State Department of Health (NYSDOH) notified CDC of detection of poliovirus type 2 in stool specimens from an unvaccinated immunocompetent young adult from Rockland County, New York, who was experiencing acute flaccid weakness. The patient initially experienced fever, neck stiffness, gastrointestinal symptoms, and limb weakness. The patient was hospitalized with possible acute flaccid myelitis (AFM). Vaccine-derived poliovirus type 2 (VDPV2) was detected in stool specimens obtained on days 11 and 12 after initial symptom onset. To date, related Sabin-like type 2 polioviruses have been detected in wastewater* in the patient's county of residence and in neighboring Orange County up to 25 days before (from samples originally collected for SARS-CoV-2 wastewater monitoring) and 41 days after the patient's symptom onset. The last U.S. case of polio caused by wild poliovirus occurred in 1979, and the World Health Organization Region of the Americas was declared polio-free in 1994. This report describes the second identification of community transmission of poliovirus in the United States since 1979; the previous instance, in 2005, was a type 1 VDPV (1). The occurrence of this case, combined with the identification of poliovirus in wastewater in neighboring Orange County, underscores the importance of maintaining high vaccination coverage to prevent paralytic polio in persons of all ages.
- Published
- 2022
7. COVID-19 Mortality Among American Indian and Alaska Native Persons — 14 States, January–June 2020
- Author
-
Jessica Arrazola, Matthew M Masiello, Abigail Echo-Hawk, Jennifer Kraszewski, Andria Apostolou, Richard Leman, Samantha K Rice, David Casey, Brooke Doman, Crisandra M Wilkie, Joshua L Clayton, Sujata Joshi, Kenneth Komatsu, Ozair Naqvi, Victoria Warren-Mears, Mike Mannell, Aaron M. Wendelboe, Pamela LeMaster, Alyssa L Rowell, Tracy K Miller, Nicholas Lehnertz, Jessica Kumar, Megan Jespersen, Amy Poel, Samantha Jh Rolland, Alison Keyser Metobo, Jonathan Bressler, Adrian Dominguez, Joe McLaughlin, Michael Landen, Bree Barbeau, Gillian Richardson, Britney Rust, and Xandy Peterson Pompa
- Subjects
medicine.medical_specialty ,Health (social science) ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,Health, Toxicology and Mutagenesis ,Population ,01 natural sciences ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Pandemic ,medicine ,Cumulative incidence ,030212 general & internal medicine ,Full Report ,0101 mathematics ,Young adult ,education ,education.field_of_study ,business.industry ,Mortality rate ,Public health ,010102 general mathematics ,General Medicine ,Confidence interval ,business ,Demography - Abstract
American Indian/Alaska Native (AI/AN) persons experienced disproportionate mortality during the 2009 influenza A(H1N1) pandemic (1,2). Concerns of a similar trend during the coronavirus disease 2019 (COVID-19) pandemic led to the formation of a workgroup* to assess the prevalence of COVID-19 deaths in the AI/AN population. As of December 2, 2020, CDC has reported 2,689 COVID-19-associated deaths among non-Hispanic AI/AN persons in the United States. A recent analysis found that the cumulative incidence of laboratory-confirmed COVID-19 cases among AI/AN persons was 3.5 times that among White persons (3). Among 14 participating states, the age-adjusted AI/AN COVID-19 mortality rate (55.8 deaths per 100,000; 95% confidence interval [CI] = 52.5-59.3) was 1.8 (95% CI = 1.7-2.0) times that among White persons (30.3 deaths per 100,000; 95% CI = 29.9-30.7). Although COVID-19 mortality rates increased with age among both AI/AN and White persons, the disparity was largest among those aged 20-49 years. Among persons aged 20-29 years, 30-39 years, and 40-49 years, the COVID-19 mortality rates among AI/AN were 10.5, 11.6, and 8.2 times, respectively, those among White persons. Evidence that AI/AN communities might be at increased risk for COVID-19 illness and death demonstrates the importance of documenting and understanding the reasons for these disparities while developing collaborative approaches with federal, state, municipal, and tribal agencies to minimize the impact of COVID-19 on AI/AN communities. Together, public health partners can plan for medical countermeasures and prevention activities for AI/AN communities.
- Published
- 2020
8. Evaluation of the Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Hospitalized Patients
- Author
-
Karen Dahri, Megan Harbin, Jane de Lemos, Isabelle Sy, Gabriel Loh, Jessica Kumar, and Felix Wei
- Subjects
medicine.medical_specialty ,COPD ,business.industry ,medicine.medical_treatment ,Pharmaceutical Science ,Retrospective cohort study ,Research Reports ,Disease ,medicine.disease ,Nicotine replacement therapy ,Community hospital ,Vaccination ,Clinical research ethics ,Emergency medicine ,Medicine ,Smoking cessation ,business - Abstract
Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are estimated to cost $1.5 billion annually in Canada. Previous studies have shown that barely half of all patients receive ideal care in hospitals. Deviations from guideline-defined optimal care lead to longer hospital stays, readmissions, and increased mortality. Objective: To determine the proportion of patients admitted to hospital for AECOPD who received treatment adherent to guidelines. Methods: A retrospective cohort study was conducted with ethics approval from the University of British Columbia Clinical Research Ethics Board. Patients hospitalized for ≥24 hours with an AECOPD at a tertiary care center and a community hospital were assessed. Guideline-adherent treatment was defined as appropriate use of supplemental oxygen, inhaled bronchodilators, systemic corticosteroids, antibiotics, venous thromboembolism prophylaxis, initiation/continuation of nicotine replacement therapy for current smokers, and vaccination optimization, reflecting international standards of care. Outcomes were assessed using descriptive statistics. Results: A random sample of 210 patients were selected of which 99 met inclusion criteria. Only 4% received therapy that met all recommendations. Differences in management were found between sites, specifically the appropriate use of bronchodilators, corticosteroids, antibiotics, and supplemental oxygen. Venous thromboembolism prophylaxis and smoking cessation rates were 97% and 94%, respectively, at the tertiary care center, compared with 73% and 100% at the community hospital. Additionally, less than half of all patients had their immunization history verified. Conclusion: Gaps in the inpatient management of AECOPD continue to exist. Initiatives must be targeted to optimize management and reduce the burden of the disease.
- Published
- 2021
9. COVID-19 Vaccine Effectiveness by Product and Timing in New York State
- Author
-
Jessica Kumar, Rebecca Hoen, Eli S. Rosenberg, Ursula E. Bauer, Vajeera Dorabwila, Danielle Greene, Delia Easton, Mary Beth Conroy, Emily Lutterloh, Howard A. Zucker, Dina Hoefer, and Meng Wu
- Subjects
2019-20 coronavirus outbreak ,education.field_of_study ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Population ,Medicine ,Waning immunity ,Prospective cohort study ,business ,education ,Demography - Abstract
BackgroundUS population-based data on COVID-19 vaccine effectiveness (VE) for the 3 currently FDA-authorized products is limited. Whether declines in VE are due to waning immunity, the Delta variant, or other causes, is debated.MethodsWe conducted a prospective study of 8,834,604 New York adults, comparing vaccine cohorts defined by product, age, and month of full-vaccination to age-specific unvaccinated cohorts, by linking statewide testing, hospital, and vaccine registry databases. VE was estimated from May 1, 2021 for incident laboratory-confirmed COVID-19 cases (weekly life-table hazard rates through September 3) and hospitalizations (monthly incidence rates through August 31).Results155,092 COVID-19 cases and 14,862 hospitalizations occurred. Estimated VE for cases declined contemporaneously across age, products, and time-cohorts, from high levels beginning May 1 (1.8% Delta variant prevalence), to a nadir around July 10 (85.3% Delta), with limited changes thereafter (>95% Delta). Decreases were greatest for Pfizer-BioNTech (−24.6%, −19.1%, −14.1% for 18-49, 50-64 years, and ≥65 years, respectively), and similar for Moderna (−18.0%, −11.6%, −9.0%, respectively) and Janssen (−19.2%, −10.8, −10.9%, respectively). VE for hospitalization for adults 18-64 years was >86% across cohorts, without time trend. Among persons ≥65 years, VE declined from May to August for Pfizer-BioNTech (95.0% to 89.2%) and Moderna (97.2% to 94.1%). VE was lower for Janssen, without trend, ranging 85.5%-82.8%.ConclusionsDeclines in VE for cases may have been primarily driven by factors other than waning. VE for hospitalizations remained high, with modest declines limited to Pfizer-BioNTech and Moderna recipients ≥65 years, supporting targeted booster dosing recommendations.
- Published
- 2021
10. Multisystem Inflammatory Syndrome in Children in New York State
- Author
-
Elizabeth Dufort, Brad Hutton, Wendy P Pulver, Lou C. Smith, Eli S. Rosenberg, Howard Zucker, Tomoko Udo, Delia Easton, Debra Blog, Emilia H. Koumans, Eric J. Chow, Angela M Maxted, Jemma Rowlands, Elizabeth M. Rosenthal, Alison Muse, Meredith A. Barranco, and Jessica Kumar
- Subjects
2019-20 coronavirus outbreak ,Pediatrics ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Recem nascido ,General Medicine ,030204 cardiovascular system & hematology ,medicine.disease ,Mucocutaneous Lymph Node Syndrome ,humanities ,Systemic inflammatory response syndrome ,03 medical and health sciences ,Pneumonia ,0302 clinical medicine ,otorhinolaryngologic diseases ,Medicine ,Viral therapy ,Original Article ,030212 general & internal medicine ,business ,Coronavirus Infections - Abstract
Background A multisystem inflammatory syndrome in children (MIS-C) is associated with coronavirus disease 2019. The New York State Department of Health (NYSDOH) established active, statewide surveillance to describe hospitalized patients with the syndrome. Methods Hospitals in New York State reported cases of Kawasaki’s disease, toxic shock syndrome, myocarditis, and potential MIS-C in hospitalized patients younger than 21 years of age and sent medical records to the NYSDOH. We carried out descriptive analyses that summarized the clinical presentation, complications, and outcomes of patients who met the NYSDOH case definition for MIS-C between March 1 and May 10, 2020. Results As of May 10, 2020, a total of 191 potential cases were reported to the NYSDOH. Of 95 patients with confirmed MIS-C (laboratory-confirmed acute or recent severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection) and 4 with suspected MIS-C (met clinical and epidemiologic criteria), 53 (54%) were male; 31 of 78 (40%) were black, and 31 of 85 (36%) were Hispanic. A total of 31 patients (31%) were 0 to 5 years of age, 42 (42%) were 6 to 12 years of age, and 26 (26%) were 13 to 20 years of age. All presented with subjective fever or chills; 97% had tachycardia, 80% had gastrointestinal symptoms, 60% had rash, 56% had conjunctival injection, and 27% had mucosal changes. Elevated levels of C-reactive protein, d-dimer, and troponin were found in 100%, 91%, and 71% of the patients, respectively; 62% received vasopressor support, 53% had evidence of myocarditis, 80% were admitted to an intensive care unit, and 2 died. The median length of hospital stay was 6 days. Conclusions The emergence of multisystem inflammatory syndrome in children in New York State coincided with widespread SARS-CoV-2 transmission; this hyperinflammatory syndrome with dermatologic, mucocutaneous, and gastrointestinal manifestations was associated with cardiac dysfunction.
- Published
- 2020
11. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
- Author
-
Tomoko Udo, Danielle Greene, David R. Holtgrave, Dina Hoefer, Brad Hutton, Shu Yin John Leung, Linda M. Styer, Rakkoo Chung, Meredith A. Barranco, Elizabeth M. Rosenthal, Howard A. Zucker, Jessica Kumar, Monica M. Parker, Eli S. Rosenberg, Johanne E. Morne, and James M. Tesoriero
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Epidemiology ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Population ,New York ,Ethnic group ,infectious diseases ,01 natural sciences ,Article ,epidemics ,Herd immunity ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,COVID-19 Testing ,Seroepidemiologic Studies ,Humans ,Medicine ,Seroprevalence ,Cumulative incidence ,030212 general & internal medicine ,0101 mathematics ,education ,Pandemics ,education.field_of_study ,seroprevalence ,Clinical Laboratory Techniques ,business.industry ,Incidence (epidemiology) ,Incidence ,Public health ,010102 general mathematics ,COVID-19 ,Middle Aged ,Confidence interval ,Coronavirus ,surveillance ,Female ,Coronavirus Infections ,business ,Contact tracing ,Demography - Abstract
ImportanceNew York State (NYS) is an epicenter of the United States’ COVID-19 epidemic. Reliable estimates of cumulative incidence of SARS-CoV-2 infection in the population are critical to tracking the extent of transmission and informing policies, but US data are lacking, in part because societal closure complicates study conduct.ObjectiveTo estimate the cumulative incidence of SARS-CoV-2 infection and percent of infections diagnosed in New York State, overall and by region, age, sex, and race and ethnicity.DesignStatewide cross-sectional seroprevalence study, conducted April 19-28, 2020.SettingGrocery stores (n=99) located in 26 counties throughout NYS, which were essential businesses that remained open during a period of societal closure and attract a heterogenous clientele.ParticipantsConvenience sample of patrons ≥18 years and residing in New York State, recruited consecutively upon entering stores and via an in-store flyer.ExposuresRegion (New York City, Westchester/Rockland, Long Island, Rest of New York State), age, sex, race and ethnicity.Main OutcomesPrimary outcome: cumulative incidence of SARS-CoV-2 infection, based on dry-blood spot (DBS) SARS-CoV-2 antibody reactivity; secondary outcome: percent of infections diagnosed.ResultsAmong 15,101 adults with suitable DBS specimens, 1,887 (12.5%) were reactive using a validated SARS-CoV-2 IgG microsphere immunoassay (sensitivity 87.9%, specificity 99.75%). Following post-stratification weighting on region, sex, age, and race and ethnicity and adjustment for assay characteristics, estimated cumulative incidence through March 29 was 14.0% (95% CI: 13.3-14.7%), corresponding to 2,139,300 (95% CI: 2,035,800-2,242,800) infection-experienced adults. Cumulative incidence was higher among Hispanic/Latino (29.2%, 95% CI: 27.2-31.2%), non-Hispanic black/African American (20.2% 95% CI, 18.1-22.3%), and non-Hispanic Asian (12.4%, 95% CI: 9.4-15.4%) adults than non-Hispanic white adults (8.1%, 95% CI: 7.4-8.7%, pConclusions and RelevanceOver 2 million adults were infected through late March 2020, with substantial variations by subpopulations. As this remains below herd immunity thresholds, monitoring, testing, and contact tracing remain essential public health strategies.
- Published
- 2020
12. Prolonged Course of Salmonella Pelvic Osteomyelitis in an Immunocompetent African American Child: A Case Report and Review of the Literature
- Author
-
Matthew Bauer, Jessica Kumar, and Michael A. Jacobs
- Subjects
African american ,Salmonella ,medicine.medical_specialty ,Debridement ,medicine.drug_class ,business.industry ,Salmonella enteritidis ,medicine.medical_treatment ,Osteomyelitis ,Antibiotics ,medicine.disease_cause ,medicine.disease ,Surgery ,Immunodeficiency Syndrome ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,030225 pediatrics ,Pediatrics, Perinatology and Child Health ,medicine ,Culture negative ,business ,030217 neurology & neurosurgery - Abstract
Salmonella pelvic osteomyelitis is an uncommon manifestation of acute hematogenous osteomyelitis in children without risk factors such as hemoglobinopathies or immunodeficiency syndromes. Here we report a case of prolonged pelvic osteomyelitis in an immunocompetent child who remained culture negative and refractory to both antibiotic therapy and nonsurgical intervention for 7 months. Definitive microbiological diagnosis and treatment were only obtained after open surgical exploration with substantial debridement. We therefore recommend earlier consideration of aggressive surgical intervention in cases of pelvic osteomyelitis in which no organism is definitively implicated or symptoms continue despite prolonged courses of antibiotics, both for source control and definitive diagnosis.
- Published
- 2017
13. Efficacy of a multi-purpose high level disinfection cabinet against Candida auris and other health care-associated pathogen
- Author
-
Jennifer L. Cadnum, Jessica Kumar, Curtis J. Donskey, and Annette L. Jencson
- Subjects
Methicillin-Resistant Staphylococcus aureus ,Ultraviolet Rays ,Epidemiology ,medicine.disease_cause ,Health care associated ,Microbiology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Peracetic acid ,Bacteriophage MS2 ,Humans ,Nonenveloped virus ,Medicine ,Potential source ,030212 general & internal medicine ,Pathogen ,Decontamination ,Candida ,0303 health sciences ,biology ,030306 microbiology ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,Hydrogen Peroxide ,biology.organism_classification ,Disinfection ,Infectious Diseases ,Candida auris ,chemistry ,Staphylococcus aureus ,business ,Delivery of Health Care - Abstract
Portable equipment and other small devices used in health care are a potential source for dissemination of pathogens. We demonstrated that a high-level disinfection cabinet using ultrasonic submicron droplets of peracetic acid and hydrogen peroxide was effective against methicillin-resistant Staphylococcus aureus, Clostridiodes difficile spores, the nonenveloped virus bacteriophage MS2, and Candida auris on steel disk carriers. The device also eliminated Candida auris inoculated on real-world items of portable equipment.
- Published
- 2020
14. Environmental Contamination with
- Author
-
Jessica, Kumar, Brandon, Eilertson, Jennifer L, Cadnum, Chauna S, Whitlow, Annette L, Jencson, Nasia, Safdar, Sarah L, Krein, Windy D, Tanner, JeanMarie, Mayer, Matthew H, Samore, and Curtis J, Donskey
- Subjects
floor and sink drain disinfection ,environmental contamination ,Candida species ,Candida auris ,infection control ,Research Article - Abstract
Background: Environmental sources have been implicated as a potential source for exogenous acquisition of Candida species, particularly the emerging multidrug-resistant Candida auris. However, limited information is available on environmental reservoirs of Candida species in healthcare facilities. Methods: During a 6-month period, cultures for Candida species were collected from high-touch surfaces in patient rooms and from portable equipment in 6 US acute care hospitals in 4 states. Additional cultures were collected from sink drains and floors in one of the hospitals and from high-touch surfaces, portable equipment, and sink drains in a hospital experiencing an outbreak due to C. auris. Candida species were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectometry. Results: Candida species were recovered from patient rooms in 4 of the 6 hospitals. Seven of 147 patient room cultures (4.8%) and 1 of 57 (1.8%) portable equipment cultures were positive, with the most common species being C. parapsilosis. For the hospital where additional sites were sampled, Candida species were recovered from 8 of 22 (36.4%) hospital room floors and 4 of 17 (23.5%) sink drains. In the facility with a C. auris outbreak, Candida species were frequently recovered from sink drains (20.7%) and high-touch surfaces (15.4%), but recovery of C. auris was uncommon (3.8% of high-touch surfaces, 3.4% of sink drains, and 0% of portable equipment) and only present in rooms that currently or recently housed a patient with C. auris. Conclusion: Candida species often contaminate surfaces in hospitals and may be particularly common on floors and in sink drains. However, C. auris contamination was uncommon in a facility experiencing an outbreak, suggesting that current cleaning and disinfection practices can be effective in minimizing environmental contamination.
- Published
- 2019
15. Evaluation of Novel 'No-Touch' Technologies for Decontamination of Toys in Pediatric Healthcare Settings
- Author
-
Curtis J. Donskey, Claudia Hoyen, Jennifer L. Cadnum, Hanan Haydar, and Jessica Kumar
- Subjects
Microbiology (medical) ,Infectious Diseases ,Epidemiology ,business.industry ,Healthcare settings ,Medicine ,Human decontamination ,Medical emergency ,business ,medicine.disease - Abstract
Background: Toys in playrooms are often shared among patients in pediatric healthcare settings; they can present a risk for transmission of bacterial and viral pathogens. Effective cleaning and disinfection of toys using disinfectant wipes is labor intensive and difficult due to irregular surfaces. Methods: We conducted a point-prevalence culture survey to determine the frequency of contamination of in-use toys and high-touch surfaces in playrooms in a pediatric healthcare facility with methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and Clostridioides difficile. Using a variety of toys inoculated with pathogens, we evaluated efficacy and ease-of-use of 3 novel “no-touch” technologies: (1) an electrostatic sprayer, (2) a small ultraviolet-C (UV-C) box (18.9 × 9.9 × 1.8 inches) for smaller toys, and (3) a high-level disinfection cabinet using ultrasonic submicron droplets of peracetic acid and hydrogen peroxide. Test pathogens included C. difficile, MRSA, and Candida auris. Results: Of 135 items cultured in playrooms, 6 (4.4%) were contaminated with MRSA, 1 (0.7%) was contaminated with VRE, and none were contaminated with C. difficile. Each of the technologies reduced all pathogens by >4 log10 CFU on all types of toys tested (plastic, soft rubber, and tablet). The electrostatic sprayer was considered the easiest to use by all users because large numbers of toys could be processed much more quickly (ie, spray for 20 seconds and allow to air dry) than with disinfectant wipes. The disinfection cabinet required 21 minutes for cycle completion, whereas the decontamination cycle for the UV box was only 30–90 seconds but with limited capacity to hold toys. Conclusions: Three “no-touch” technologies were effective for disinfection of toys contaminated with healthcare-associated pathogens. The electrostatic spray application of disinfectant was considered the easiest to use for rapid decontamination of toys.Funding: NoneDisclosures: None
- Published
- 2020
16. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- Author
-
Elizabeth Dufort, James M. Tesoriero, Jack DeHovitz, Brad Hutton, Tomoko Udo, Larissa A. Wilberschied, Howard A. Zucker, Alison Muse, David R. Holtgrave, Jessica Kumar, James N Kirkwood, Eli S. Rosenberg, Patti Weinberg, and Debra Blog
- Subjects
medicine.medical_specialty ,Proportional hazards model ,business.industry ,010102 general mathematics ,Hydroxychloroquine ,Retrospective cohort study ,General Medicine ,Azithromycin ,01 natural sciences ,QT interval ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Internal medicine ,medicine ,030212 general & internal medicine ,0101 mathematics ,Adverse effect ,business ,Original Investigation ,Cohort study ,medicine.drug - Abstract
Importance Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events. Objective To describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19. Design, Setting, and Participants Retrospective multicenter cohort study of patients from a random sample of all admitted patients with laboratory-confirmed COVID-19 in 25 hospitals, representing 88.2% of patients with COVID-19 in the New York metropolitan region. Eligible patients were admitted for at least 24 hours between March 15 and 28, 2020. Medications, preexisting conditions, clinical measures on admission, outcomes, and adverse events were abstracted from medical records. The date of final follow-up was April 24, 2020. Exposures Receipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither. Main Outcomes and Measures Primary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation). Results Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O2saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L. Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%). The probability of death for patients receiving hydroxychloroquine + azithromycin was 189/735 (25.7% [95% CI, 22.3%-28.9%]), hydroxychloroquine alone, 54/271 (19.9% [95% CI, 15.2%-24.7%]), azithromycin alone, 21/211 (10.0% [95% CI, 5.9%-14.0%]), and neither drug, 28/221 (12.7% [95% CI, 8.3%-17.1%]). In adjusted Cox proportional hazards models, compared with patients receiving neither drug, there were no significant differences in mortality for patients receiving hydroxychloroquine + azithromycin (HR, 1.35 [95% CI, 0.76-2.40]), hydroxychloroquine alone (HR, 1.08 [95% CI, 0.63-1.85]), or azithromycin alone (HR, 0.56 [95% CI, 0.26-1.21]). In logistic models, compared with patients receiving neither drug cardiac arrest was significantly more likely in patients receiving hydroxychloroquine + azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or azithromycin alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]), . In adjusted logistic regression models, there were no significant differences in the relative likelihood of abnormal electrocardiogram findings. Conclusions and Relevance Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.
- Published
- 2020
17. Plasma Selenium Concentrations Are Sufficient and Associated with Protease Inhibitor Use in Treated HIV-Infected Adults
- Author
-
Jessica Kumar, Gerald F. Combs, Suet Kam Lam, Sahera Dirajlal-Fargo, Grace A. McComsey, Craig Lacher, and Corrilynn O. Hileman
- Subjects
inorganic chemicals ,Adult ,Male ,medicine.medical_specialty ,Antioxidant ,Statin ,Nutrition and Disease ,medicine.drug_class ,medicine.medical_treatment ,Population ,Nutritional Status ,Medicine (miscellaneous) ,chemistry.chemical_element ,HIV Infections ,Cohort Studies ,Selenium ,Double-Blind Method ,Risk Factors ,Selenium deficiency ,Internal medicine ,medicine ,Humans ,Rosuvastatin ,Vascular Diseases ,Rosuvastatin Calcium ,education ,Ohio ,Subclinical infection ,education.field_of_study ,Nutrition and Dietetics ,business.industry ,Vascular disease ,food and beverages ,HIV Protease Inhibitors ,Middle Aged ,medicine.disease ,Endocrinology ,chemistry ,Asymptomatic Diseases ,HIV-1 ,RNA, Viral ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Deficiency Diseases ,business ,Biomarkers ,Follow-Up Studies ,medicine.drug - Abstract
Background: Selenium is an essential constituent of selenoproteins, which play a substantial role in antioxidant defense and inflammatory cascades. Selenium deficiency is associated with disease states characterized by inflammation, including cardiovascular disease (CVD). Although HIV infection has been associated with low selenium, the role of selenium status in HIV-related CVD is unclear. Objectives: We sought to assess associations between plasma selenium and markers of inflammation, immune activation, and subclinical vascular disease in HIV-infected adults on contemporary antiretroviral therapy (ART) and to determine if statin therapy modifies selenium status. Methods: In the Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN trial, HIV-infected adults on stable ART were randomly assigned 1:1 to rosuvastatin or placebo. Plasma selenium concentrations were determined at entry, week 24, and week 48. Spearman correlation and linear regression analyses were used to assess relations between baseline selenium, HIV-related factors and markers of inflammation, immune activation, and subclinical vascular disease. Changes in selenium over 24 and 48 wk were compared between groups. Results: One hundred forty-seven HIV-infected adults were included. All participants were on ART. Median current CD4+ count was 613, and 76% had HIV-1 RNA ≤48 copies/mL (range
- Published
- 2015
18. Chronic Thromboembolic Pulmonary Hypertension: Epidemiology, Diagnosis, and Management
- Author
-
Wilbert S. Aronow, Ramin Malekan, Sohaib Tariq, Srikanth Yandrapalli, Jessica Kumar, Gregg M. Lanier, and William H. Frishman
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Hypertension, Pulmonary ,Population ,Perfusion scanning ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Angioplasty ,Thromboembolism ,Pulmonary angiography ,Medicine ,Humans ,Thrombus ,education ,education.field_of_study ,business.industry ,General Medicine ,medicine.disease ,Pulmonary hypertension ,Pulmonary embolism ,030228 respiratory system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Pulmonary Embolism ,Rare disease - Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH), classified as World Health Organization (WHO) group 4 pulmonary hypertension (PH), is an interesting and rare pulmonary vascular disorder secondary to mechanical obstruction of the pulmonary vasculature from thromboembolism resulting in PH. The pathophysiology is complex, beginning with mechanical obstruction of the pulmonary arteries, which eventually leads to arteriopathic changes and vascular remodeling in the nonoccluded arteries and in the distal segments of the occluded arteries mediated by thrombus nonresolution, abnormal angiogenesis, endothelial dysfunction, and various local growth factors. Based on available data, CTEPH is a rare disease entity occurring in a small proportion (0.5-3%) of patients after acute pulmonary embolism with an annual incidence ranging anywhere between 1 and 7 cases per million population. It is often underdiagnosed or misdiagnosed as idiopathic pulmonary arterial hypertension due to a lack of clinical suspicion or the under-utilization of radionuclide ventilation/perfusion scan. Although the current standard remains planar ventilation/perfusion scintigraphy as the initial imaging study to screen for CTEPH, and invasive pulmonary angiography with right heart catheterization as confirmatory modalities, they are likely to be replaced by modalities that can provide both anatomic and functional data while minimizing radiation exposure. Surgery is the gold standard treatment and offers better improvements in clinical and hemodynamic parameters compared with medical therapy. The management of CTEPH requires a multidisciplinary team, operability assessment, experienced surgical center, and the consideration of medical PH-directed therapies in patients who have inoperable disease, in addition to supportive therapies. Although, balloon pulmonary angioplasty is gaining interest to improve pulmonary hemodynamics and symptoms in CTEPH patients not amenable to surgery, further investigative randomized studies are needed to validate its use. It is very important for the present-day physician to be familiar with the disease entity and its appropriate evaluation to facilitate early diagnosis and appropriate management.
- Published
- 2017
19. Intracytoplasmic Granulocytic Morulae Counts on Confirmed Cases of Ehrlichiosis/Anaplasmosis in the Northeast
- Author
-
Ashley J Tarasen, Suzanne M. Homan, Jessica Kumar, Janne V. Rand, and Ellis H. Tobin
- Subjects
Male ,Anaplasmosis ,Pathology ,medicine.medical_specialty ,Human granulocytic anaplasmosis ,Cost effectiveness ,Biology ,Granulocyte ,Leukocyte Count ,Bovine Anaplasmosis ,medicine ,Humans ,reproductive and urinary physiology ,Aged ,Retrospective Studies ,Aged, 80 and over ,Ehrlichiosis ,General Medicine ,Middle Aged ,medicine.disease ,United States ,medicine.anatomical_structure ,embryonic structures ,Immunology ,Ehrlichiosis (canine) ,Female ,Granulocytes - Abstract
Objectives To characterize the number of granulocytes needed to count on peripheral smear to identify diagnostic anaplasmosis morulae. Methods Retrospective case study where the peripheral smears of 14 confirmed cases of anaplasmosis were examined. The granulocytes were counted up to 100 and 200 until a morula was identified. The mean counts of three pathologists were calculated to determine the minimum number of granulocytes needed to count for identifying diagnostic morulae. Results Morulae were identified before a count of 100 granulocytes in 11 (78.6%) cases and between 100 and 200 granulocytes in 3 (21.4%) cases. All 14 (100%) cases had morulae identified before counting 200 granulocytes. Conclusions Peripheral smears are a useful, cost-effective, and time-effective tool for diagnosing anaplasmosis. In positive cases, diagnostic morulae can be identified with a count of 200 granulocytes.
- Published
- 2014
20. 1222. Are Reduced Concentrations of Chlorine-Based Disinfectants Effective Against Candida auris?
- Author
-
Y Karen Ng Wong, Heba Alhmidi, Thriveen Sankar Chittoor Mana, Jessica Kumar, Jennifer L. Cadnum, and Curtis J. Donskey
- Subjects
Bleach ,business.industry ,Sodium ,chemistry.chemical_element ,Pathogenic organism ,Microbiology ,chemistry.chemical_compound ,Abstracts ,Infectious Diseases ,Oncology ,Candida auris ,chemistry ,Sodium hypochlorite ,Poster Abstracts ,Chlorine ,Medicine ,Microbial colonization ,business ,Patient simulation - Abstract
Background Currently, sporicidal disinfectants such as bleach are recommended for daily and terminal disinfection of the rooms of patients with Candida auris colonization and/or infection. However, bleach and other chlorine-based disinfectants can have adverse effects on surfaces and personnel. Disinfectant solutions with reduced chlorine concentrations are commonly used for other pathogens, but it is not known if diluted or alternative products maintain efficacy against C. auris both in vitro and in vivo. Methods We tested the efficacy of different concentrations of a sodium dichloroisocyanurate (NaDCC) product and sodium hypochlorite using the method recommended by the Environmental Protection Agency (EPA) for evaluation of the efficacy of liquid disinfectants against C. auris (EPA MLB SOP MB-35-00) and in a simulated patient room. Carriers were exposed to each disinfectant for 1 and 2 minutes. Log reductions were calculated by subtracting viable organisms recovered after disinfectant exposure vs. deionized water controls. Results As shown in the figure, the NaDCC product at 4306 ppm tested with a 2 minute contact time reduced C. auris by ≥5 log10 colony-forming units (CFU) but had reduced efficacy with shorter exposure time or lower concentrations. Sodium hypochlorite was effective with 1 or 2 minute exposure times at a concentration of 6,500 ppm, and was effective at 4,000 ppm with an exposure time of 2 minutes. In the simulated patient room, NaDCC reduced C. auris contamination by ≥6 log10 CFUs on all surfaces. Conclusion A chlorine-based NaDCC product was effective at reducing C. auris. Both NaDCC and sodium hypochlorite products exhibited reduced efficacy at lower concentrations, particularly at concentrations below 4000 ppm. The NaDCC products were also effective in reducing contamination in the simulated patient room. UV-C treatment was an effective adjunct to manual cleaning. Disclosures All authors: No reported disclosures.
- Published
- 2019
21. How to promote justice, greater safety and trust between hospitals and patients
- Author
-
Nicole Reinhardt, William P. Dillon, Steven E. Pegalis, Daniel Pelo, and Jessica Kumar
- Subjects
business.industry ,Specialty ,Justice (ethics) ,Public relations ,Legal case ,business ,Psychology ,Learning from errors - Abstract
In a time when lack of trust has been cited as an increasing problem between patients and the organizations and physicians who care for them, what can hospitals and physicians do to deal with this problem that is not already being done? We discuss herein an actual obstetrical based legal case intended to be an illustrative example of medical-legal issues that could apply to any specialty. If hospitals and physicians will overtly promote safety by learning from errors and support justice for injured patients, the conveyance of these ethically motivated policies to the public can be a powerful message that hospitals and physicians are to be trusted.
- Published
- 2019
22. Successful surgical intervention for the management of endocarditis due to multidrug resistant Candida parapsilosis: case report and literature review
- Author
-
Vishnu Chaturvedi, Harold Burger, Jessica Kumar, Douglas N. Fish, Karl Robstad, Jeffrey S. Ross, Barbara Weiser, David M. Jones, and Xiaojiang Li
- Subjects
Male ,medicine.medical_specialty ,Antifungal Agents ,Veterinary (miscellaneous) ,HIV Infections ,Drug resistance ,Candida parapsilosis ,Applied Microbiology and Biotechnology ,Microbiology ,Asymptomatic ,Medical microbiology ,Internal medicine ,Drug Resistance, Multiple, Fungal ,medicine ,Endocarditis ,Humans ,Fungemia ,Candida ,biology ,business.industry ,Mortality rate ,Candidiasis ,Hepatitis C ,Middle Aged ,medicine.disease ,biology.organism_classification ,Surgery ,Treatment Outcome ,medicine.symptom ,business ,Agronomy and Crop Science - Abstract
Candida parapsilosis is an uncommon cause of invasive endocarditis. This pathogen induces severe complications and carries a high mortality rate. We describe a case of C. parapsilosis endocarditis in a 54-year-old man with a history of HIV and Hepatitis C infection who previously underwent prosthetic valve replacement due to bacterial endocarditis. The patient presented with prolonged febrile episodes and fungemia with repeat blood cultures positive for C. parapsilosis. The patient failed multiple regimens of antifungal therapy and the C. parapsilosis isolate progressively acquired resistance to a number of drugs. Due to the multidrug resistant nature of the isolate, replacement of the infected valve was required to resolve his fungemia, and the patient remained asymptomatic for two years. This case is unusual due to the multidrug resistant nature of the isolate requiring both combined medical and surgical intervention. A review of published reports indicates that endocarditis due to C. parapsilosis responds well to a combination of medical and surgical interventions; the latter is particularly suitable for immunocompromised hosts.
- Published
- 2010
23. Breast-feeding history and overweight in Latino preschoolers
- Author
-
Ronald A. Thisted, Monica Sanchez-Rosado, Rebecca Lipton, Margaret Kersey, John D. Lantos, and Jessica Kumar
- Subjects
Male ,Percentile ,Pediatrics ,medicine.medical_specialty ,Overweight ,Risk Assessment ,Mexican Americans ,Outpatient clinic ,Medicine ,Humans ,business.industry ,General Medicine ,Odds ratio ,Emigration and Immigration ,Health history ,Breast Feeding ,Reference values ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,medicine.symptom ,business ,Breast feeding ,Body mass index ,Demography - Abstract
Objective.— Describe the relationship between breast-feeding history and risk of overweight in the preschool years in a sample of primarily Mexican-origin Latinos. Methods.— Children's breast-feeding history, health history, and demographics were obtained in interviewer-administered questionnaires of a convenience sample of 364 parents of children ages 2–5 in an outpatient clinic waiting room serving a predominantly Mexican immigrant population in a large Midwestern city. Child weight status was determined by weighing and measuring each child and calculating age- and sex-specific body mass index (BMI) percentile using 2000 Centers for Disease Control reference values, with children ≥95th percentile defined as overweight. Results.— Seventy-six of 364 children (21%) were overweight. Eighty-seven percent of children had been breast-fed. Increased duration of breast-feeding was associated with a linearly decreased risk of overweight in bivariate analysis, ranging from an overweight prevalence of 35% for those never breast-fed to 12% for those breast-fed for at least a year. This inverse relationship remained significant in the smaller sample for which maternal BMI data were available (n = 127), as each additional month of breast-feeding was associated with a 10% decreased odds ratio (OR) of overweight (adjusted OR=0.90; 95% CI=0.81, 0.99) after controlling for child's sex, current age, prematurity, birth-weight category, maternal education level, and maternal weight status. Conclusion.— This sample of children of Mexican-origin immigrant families had high rates of overweight at very young ages but also very high rates of breast-feeding. Duration of breast-feeding was strongly and inversely related with prevalence of overweight as a preschooler.
- Published
- 2005
24. LUNG ABSCESS CAUSED BY SOLOBACTERIUM MOOREI IN A PATIENT WITH SEVERE COPD
- Author
-
Anwar M. Haque, Scott Beegle, and Jessica Kumar
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,biology ,business.industry ,Lung abscess ,Severe copd ,Critical Care and Intensive Care Medicine ,biology.organism_classification ,medicine.disease ,Surgery ,Solobacterium moorei ,Medicine ,Cardiology and Cardiovascular Medicine ,business - Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.